Cargando…

New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury

Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia‐reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone‐related compound, exhibits antiplatelet and anti‐inflammatory ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Wan‐Jung, Lin, Kuan‐Hung, Tseng, Mei‐Fang, Yuan, Kuo‐Ching, Huang, Hung‐Chang, Sheu, Joen‐Rong, Chen, Ray‐Jade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378182/
https://www.ncbi.nlm.nih.gov/pubmed/30548082
http://dx.doi.org/10.1111/jcmm.14070
_version_ 1783395879449788416
author Lu, Wan‐Jung
Lin, Kuan‐Hung
Tseng, Mei‐Fang
Yuan, Kuo‐Ching
Huang, Hung‐Chang
Sheu, Joen‐Rong
Chen, Ray‐Jade
author_facet Lu, Wan‐Jung
Lin, Kuan‐Hung
Tseng, Mei‐Fang
Yuan, Kuo‐Ching
Huang, Hung‐Chang
Sheu, Joen‐Rong
Chen, Ray‐Jade
author_sort Lu, Wan‐Jung
collection PubMed
description Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia‐reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone‐related compound, exhibits antiplatelet and anti‐inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R‐induced hepatic injury. Hinokitiol could inhibited NF‐κB activation and IL‐6 and TNF‐α upregulation in liver tissues. Moreover, hinokitiol reduced caspase‐3 activation, upregulated Bax and downregulated Bcl‐2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)‐induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R‐induced caspase‐3 activation, PPAR cleavage, Bax overexpression and Bcl‐2 downregulation. Moreover, hinokitiol attenuated H/R‐stimulated NF‐κB activation and reduced the levels of IL‐6 and TNF‐α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF‐κB activation.
format Online
Article
Text
id pubmed-6378182
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63781822019-03-01 New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury Lu, Wan‐Jung Lin, Kuan‐Hung Tseng, Mei‐Fang Yuan, Kuo‐Ching Huang, Hung‐Chang Sheu, Joen‐Rong Chen, Ray‐Jade J Cell Mol Med Original Articles Haemorrhagic shock and resuscitation (HS/R) may cause global ischaemia‐reperfusion injury, which can result in systemic inflammation, multiorgan failure (particularly liver failure) and high mortality. Hinokitiol, a bioactive tropolone‐related compound, exhibits antiplatelet and anti‐inflammatory activities. Targeting inflammatory responses is a potential strategy for ameliorating hepatic injury during HS/R. Whether hinokitiol prevents hepatic injury during HS/R remains unclear. In the present study, we determined the role of hinokitiol following HS/R. The in vivo assays revealed that hinokitiol markedly attenuated HS/R‐induced hepatic injury. Hinokitiol could inhibited NF‐κB activation and IL‐6 and TNF‐α upregulation in liver tissues. Moreover, hinokitiol reduced caspase‐3 activation, upregulated Bax and downregulated Bcl‐2. These findings suggest that hinokitiol can ameliorate liver injury following HS/R, partly through suppression of inflammation and apoptosis. Furthermore, the in vitro data revealed that hinokitiol significantly reversed hypoxia/reoxygenation (H/R)‐induced cell death and apoptosis in the primary hepatocytes. Hinokitiol prevented H/R‐induced caspase‐3 activation, PPAR cleavage, Bax overexpression and Bcl‐2 downregulation. Moreover, hinokitiol attenuated H/R‐stimulated NF‐κB activation and reduced the levels of IL‐6 and TNF‐α mRNAs, suggesting that hinokitiol can protect hepatocytes from H/R injury. Collectively, our data suggest that hinokitiol attenuates liver injury following HS/R, partly through the inhibition of NF‐κB activation. John Wiley and Sons Inc. 2018-12-08 2019-03 /pmc/articles/PMC6378182/ /pubmed/30548082 http://dx.doi.org/10.1111/jcmm.14070 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lu, Wan‐Jung
Lin, Kuan‐Hung
Tseng, Mei‐Fang
Yuan, Kuo‐Ching
Huang, Hung‐Chang
Sheu, Joen‐Rong
Chen, Ray‐Jade
New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title_full New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title_fullStr New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title_full_unstemmed New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title_short New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
title_sort new therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378182/
https://www.ncbi.nlm.nih.gov/pubmed/30548082
http://dx.doi.org/10.1111/jcmm.14070
work_keys_str_mv AT luwanjung newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT linkuanhung newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT tsengmeifang newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT yuankuoching newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT huanghungchang newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT sheujoenrong newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury
AT chenrayjade newtherapeuticstrategyofhinokitiolinhaemorrhagicshockinducedliverinjury